INTRODUCTION {#s1}
============

Renal cell carcinoma (RCC) is the most common malignancy of the kidney, accounting for approximately 80%-85% of all renal tumors \[[@R1]\]. Until now, many influencing factors have been identified that might increase the risk of RCC, including tobacco smoking, hypertension and occupational exposures to chemicals \[[@R2], [@R3]\]. However, even if many people are exposed to these risk factors, only a few of them develop RCC. This suggests that genetic factors may have a critical influence on the aetiology of RCC. Several studies have confirmed the role of genetic factors in the development of RCC \[[@R4], [@R5]\].

Angiogenesis is the formation of new blood vessels from endothelial precursors and it is one of the fundamental processes in carcinogenesis \[[@R6], [@R7]\]. It is well known that angiogenesis is correlated with tumor progression and metastasis \[[@R8]\]. Vascular endothelial growth factor (VEGF), known as a critical angiogenesis factor, could promote tumor development and progression both *in vitro* and *in vivo* experiments \[[@R9]--[@R11]\]. Meanwhile, tumor-induced angiogenesis and growth could be suppressed by inhibiting VEGF signaling \[[@R12], [@R13]\]. The gene encoding VEGF, which comprises a 14-kb coding region with 8 exons, is located at chromosome 6p21.3 \[[@R14]\]. There are many single nucleotide polymorphisms (SNPs) identified in the VEGF gene, which can alter the expression level of this gene and confer individual susceptibility to tumor \[[@R15], [@R16]\].

Compared to healthy renal tissue, the VEGF expression level is higher in RCC tissue \[[@R17]\]. Moreover, specific drugs targeting VEGF have shown clinical effcacy in the treatment of RCC \[[@R18], [@R19]\]. Therefore, VEGF polymorphisms may be associated with the progression and prognosis of RCC. Several SNPs, such as VEGF -2578C/A, −1156G/A, +1612G/A, +936C/T, and -634G/C, have been reported to be associated with cancer susceptibility, tumor growth and metastases in RCC patients \[[@R20]--[@R22]\]. However, because of the limited sample size, these studies showed the results remained inconclusive. Thus, we performed a systemic review and an updated meta-analysis including all eligible case-control studies to investigate whether VEGF polymorphisms were associated with the risk and prognosis of RCC.

RESULTS {#s2}
=======

Studies characteristics {#s2_1}
-----------------------

According to the searching criteria, a total of related 232 articles through a primary search of databases and reference lists were initially identified. As a result, of these articles, 14 full-text studies met the inclusion criteria and were involved in the present meta-analysis for a more further evaluation, which had been accrued between November 2002 and September 2016 \[[@R21]--[@R34]\]. Besides, all studies suggested that the distribution of genotypes in the controls was consistent between HWE. The flowchart of literature search and selection procedure is shown in Figure [1](#F1){ref-type="fig"}. In this meta-analysis, all of the baseline characteristics of the studies associated with the risk and prognosis of RCC are comprehensively listed in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}. Among all the SNPs of the VEGF gene addressed, −2578C/A, +936C/T, +1612G/A, −634G/C, +460T/C, +405 G/C, −1154G/A were the most common. Among these 14 enrolled studies, there were 10 studies based on Asian population and 4 studies conducted in Caucasians population.

![The flowchart of literature search and selection procedure](oncotarget-08-50034-g001){#F1}

###### Baseline characteristics of studies associated with the risk of RCC included in the meta-analysis

  Ref.         Year   Surname       Ethnicity   SOC   Genotyping   Cases   Controls   Gene polymorphism                             NOS   HWE
  ------------ ------ ------------- ----------- ----- ------------ ------- ---------- --------------------------------------------- ----- -----
  \[[@R26]\]   2015   Yang          Asian       HB    Taqman       191     376        −2578C/A, −1154G/A, −634G/C, +936C/T          6     Y
  \[[@R23]\]   2015   Shen          Asian       HB    PCR-RFLP     360     360        −2578C/A, +1612G/A, +936C/T, −634G/C          5     Y
  \[[@R24]\]   2015   Xian          Asian       HB    PCR-RFLP     266     532        −2578C/A, +1612G/A, +936C/T, −634G/C          5     Y
  \[[@R25]\]   2015   Lu            Asian       HB    PCR-RFLP     412     824        −2578C/A,+1612G/A,+460T/C, +936C/T, −634G/C   5     Y
  \[[@R27]\]   2014   Qin           Asian       HB    Taqman       859     1004       +405G/C                                       7     Y
  \[[@R28]\]   2013   Sáenz-López   Caucasian   HB    Taqman       216     280        −2578C/A, +460T/C, +405G/C, +936C/T           6     Y
  \[[@R29]\]   2011   Ajaz          Asian       HB    PCR-RFLP     143     106        −2578C/A,+936C/T                              5     Y
  \[[@R30]\]   2010   Bruyère       Caucasian   HB    PCR-RFLP     51      202        +460T/C, +405G/C, +936C/T, −1154G/A           5     Y
  \[[@R31]\]   2009   Ricketts      Caucasian   HB    PCR-RFLP     317     295        −1154G/A                                      6     Y
  \[[@R32]\]   2002   Abe           Asian       HB    PCR-RFLP     145     145        +936C/T, +1612G/A                             5     Y

SOC: source of control; HB: hospital-based; HWE: Hardy--Weinberg equilibrium.

NOS: Newcastle-Ottawa Scale

###### Baseline characteristics of studies associated with the prognosis of RCC included in the meta-analysis

  Ref.         Year   Surname   Ethnicity   Genotyping   Cases   Gene polymorphism             Survival analysis   Source of HR   Max months for follow-up   NOS
  ------------ ------ --------- ----------- ------------ ------- ----------------------------- ------------------- -------------- -------------------------- -----
  \[[@R33]\]   2015   Ma        Asian       PCR-RFLP     310     −2578C/A, −1154G/A, −634C/G   OS                  Reported       60                         7
  \[[@R34]\]   2015   Yang      Asian       PCR-RFLP     336     −2578C/A, −1154G/A, −634C/G   OS                  Reported       60                         6
  \[[@R21]\]   2014   Zhong     Asian       PCR-RFLP     332     −2578C/A, −1154G/A, −634C/G   OS                  Reported       60                         5
  \[[@R22]\]   2007   Kawai     Caucasian   PCR-RFLP     213     −2578C/A, −1154G/A, −634C/G   OS                  Reported       160                        6

HR: hazard ratio; OS: overall survival; NOS: Newcastle-Ottawa Scale.

Quantitative synthesis results {#s2_2}
------------------------------

Overall, the strength of association between VEGF genetic polymorphisms and RCC risk was evaluated by the pooled ORs with 95% CIs based on five genetic comparison models. A summary of all the meta-analysis results for the seven studied VEGF polymorphisms and RCC susceptibility is provided in Table [3](#T3){ref-type="table"}. In addition, the results of subgroup analysis by ethnicity is shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

###### Meta-analysis results for the seven studied polymorphisms and RCC risk

  Genotype comparison                             OR \[95% CI\]         Heterogeneity-test   Model   
  ----------------------------------------------- --------------------- -------------------- ------- --------
  **VEGF -2578C/A (1588 cases, 2470 controls)**                                                      
  A vs C (Allele model)                           1.30 \[1.18, 1.43\]   0.689                0       Fixed
  AA vs CC (Homozygous model)                     1.60 \[1.31, 1.96\]   0.430                0       Fixed
  CA vs CC (Heterozygous model)                   1.24 \[1.08, 1.43\]   0.062                52.4    Fixed
  AA+CA vs CC (Dominant model)                    1.31 \[1.15, 1.50\]   0.051                54.5    Fixed
  AA vs CA+CC (Recessive model)                   1.39 \[1.16, 1.67\]   0.626                0       Fixed
  **VEGF +936C/T (1636 cases, 2712 controls)**                                                       
  T vs C (Allele model)                           1.16 \[1.05,1.29\]    0.130                39.3    Fixed
  TT vs CC (Homozygous model)                     1.33 \[1.08, 1.65\]   0.236                25.3    Fixed
  CT vs CC (Heterozygous model)                   1.13 \[0.97, 1.30\]   0.246                23.9    Fixed
  TT+CT vs CC (Dominant model)                    1.16 \[1.02, 1.33\]   0.123                40.2    Fixed
  TT vs CT+CC (Recessive model)                   1.25 \[1.02, 1.52\]   0.478                0       Fixed
  **VEGF +1612G/A (1184 cases, 1862 controls)**                                                      
  A vs G (Allele model)                           1.08 \[1.00,1.17\]    0.639                0       Fixed
  AA vs GG (Homozygous model)                     1.33 \[1.02, 1.74\]   0.527                0       Fixed
  GA vs GG (Heterozygous model)                   1.09 \[0.93, 1.27\]   0.919                0       Fixed
  AA+GA vs GG (Dominant model)                    1.12 \[0.96, 1.30\]   0.760                0       Fixed
  AA vs GA+GG (Recessive model)                   1.27 \[0.99, 1.64\]   0.558                0       Fixed
  **VEGF -634G/C (1229 cases, 2092 controls)**                                                       
  C vs G (Allele model)                           1.11 \[1.00,1.23\]    0.882                0       Fixed
  CC vs GG (Homozygous model)                     1.22 \[0.99, 1.51\]   0.964                0       Fixed
  GC vs GG (Heterozygous model)                   1.13 \[0.96, 1.32\]   0.998                0       Fixed
  CC+GC vs GG (Dominant model)                    1.15 \[0.99, 1.33\]   0.994                0       Fixed
  CC vs GC+GG (Recessive model)                   1.14 \[0.94, 1.38\]   0.961                0       Fixed
  **VEGF +460T/C (677 cases, 1299 controls)**                                                        
  C vs T (Allele model)                           0.92 \[0.58,1.46\]    0.000                87.9    Random
  CC vs TT (Homozygous model)                     0.88 \[0.38, 2.01\]   0.006                80.6    Random
  TC vs TT (Heterozygous model)                   1.12 \[0.89, 1.41\]   0.235                31      Fixed
  CC+TC vs TT (Dominant model)                    0.98 \[0.61, 1.58\]   0.017                75.5    Random
  CC vs TC+TT (Recessive model)                   1.10 \[0.87, 1.39\]   0.011                77.9    Random
  **VEGF +405 G/C (1086 cases, 1460 controls)**                                                      
  C vs G (Allele model)                           1.18 \[1.05,1.33\]    0.113                54.1    Fixed
  CC vs GG (Homozygous model)                     1.35 \[1.06,1.72\]    0.125                51.8    Fixed
  GC vs GG (Heterozygous model)                   1.25 \[1.05,1.48\]    0.407                0       Fixed
  CC+GC vs GG (Dominant model)                    1.27 \[1.08,1.49\]    0.191                39.5    Fixed
  CC vs GC+GG (Recessive model)                   1.06 \[0.84,1.33\]    0.628                0       Fixed
  **VEGF -1154G/A (564 cases, 892 controls)**                                                        
  A vs G (Allele model)                           1.04 \[0.88,1.24\]    0.228                32.3    Fixed
  AA vs GG (Homozygous model)                     1.07 \[0.73,1.57\]    0.330                9.7     Fixed
  GA vs GG (Heterozygous model)                   1.06 \[0.84,1.35\]    0.392                0       Fixed
  AA+GA vs GG (Dominant model)                    1.06 \[0.84,1.32\]    0.266                24.4    Fixed
  AA vs GA+GG (Recessive model)                   1.04 \[0.72,1.51\]    0.493                0       Fixed

-2578C/A and RCC risk {#s2_3}
---------------------

The combined results of all analyses showed that the pooled OR of these six studies was 1.30 (95% CI: 1.18-1.43) for allele model, 1.60 (95% CI: 1.31-1.96) for homozygote model, 1.24 (95% CI: 1.08-1.43) for heterozygote model, 1.31 (95% CI: 1.15-1.50) for dominant model and 1.39 (95% CI: 1.16-1.67) for recessive model, which indicated a strong association between VEGF -2578C/A mutation and RCC susceptibility. Furthermore, subgroups analysis by ethnicity was performed to establish the effects of heterogeneity on the results. In the subgroup analysis by ethnicity, the results were significant in Asian populations rather than Caucasians population in all genetic models, including allele model: pooled OR=1.33, 95% CI: 1.20-1.47; homozygote model: pooled OR=1.67, 95% CI: 1.34-2.07; heterozygote model: pooled OR=1.30, 95% CI: 1.01-1.67; dominant model: pooled OR=1.36, 95% CI: 1.07-1.73; recessive model: pooled OR=1.44, 95% CI: 1.18-1.76 (Figure [2](#F2){ref-type="fig"}).

![Forest plot of the association between the -2578C/A polymorphism and RCC risk\
**(A)** allele model; **(B)** homozygote model; **(C)** heterozygote model; **(D)** dominant model; **(E)** recessive model.](oncotarget-08-50034-g002){#F2}

+936C/T and RCC risk {#s2_4}
--------------------

Significant differences were found between VEGF +936C/T polymorphism and RCC risk using allele model: pooled OR=1.16, 95% CI: 1.05-1.29; homozygote model: pooled OR=1.33, 95% CI: 1.08-1.65; dominant model: pooled OR=1.16, 95% CI: 1.02-1.33; recessive model: pooled OR=1.25, 95% CI: 1.02-1.52. When the studies were stratified by ethnicity, significant differences were observed in Asian population in those models (allele model: pooled OR=1.18, 95% CI: 1.06-1.32; homozygote model: pooled OR=1.37, 95% CI: 1.11-1.70; dominant model: pooled OR=1.18, 95% CI: 1.02-1.36; recessive model: pooled OR=1.27, 95% CI: 1.04-1.56), but, no significant results were detected in Caucasian population (Figure [3](#F3){ref-type="fig"}).

![Forest plot of the association between the +936C/A polymorphism and RCC risk\
**(A)** allele model; **(B)** homozygote model; **(C)** dominant model; **(D)** recessive model.](oncotarget-08-50034-g003){#F3}

+1612G/A and RCC risk {#s2_5}
---------------------

In the present meta-analysis, the results demonstrated that the VEGF +1612G/A polymorphism was significant correlated with RCC only in allele model (pooled OR = 1.08, 95% CI: 1.00-1.17) and homozygote model (pooled OR = 1.33, 95% CI: 1.02-1.74) (Figure [4](#F4){ref-type="fig"}).

![Forest plot of the association between the +1612C/A polymorphism and RCC risk\
**(A)** allele model; **(B)** dominant model.](oncotarget-08-50034-g004){#F4}

-634G/C and RCC risk {#s2_6}
--------------------

No statistically significant association between VEGF -634G/C polymorphism and RCC susceptibility was assessed in all genetic comparison models and the stratified analysis by ethnicity.

+460T/C and RCC risk {#s2_7}
--------------------

The pooled analysis has shown that the VEGF +460T/C polymorphism was not significantly associated with RCC susceptibility in all five genetic models. However, when the studies were stratified by ethnicity, the positive result was detected in Asian population for allele model (pooled OR = 1.32, 95% CI: 1.10-1.58), dominant model (pooled OR = 1.33, 95% CI: 1.05-1.69) and recessive model (pooled OR = 1.35, 95% CI: 1.01-1.81) (Figure [5](#F5){ref-type="fig"}).

![Forest plot of the association between the +460C/A polymorphism and RCC risk\
**(A)** allele model; **(B)** homozygote model; **(C)** recessive model.](oncotarget-08-50034-g005){#F5}

+405 G/C and RCC risk {#s2_8}
---------------------

The combined results of all analyses showed that the pooled OR of these studies was 1.18 (95% CI: 1.05-1.33) for allele model, 1.35 (95% CI: 1.06-1.72) for homozygote model and 1.25 (95% CI: 1.05-1.48) for heterozygote model and 1.27(95% CI: 1.08-1.49) for dominant model, which indicated a significant association between VEGF +405 G/C polymorphism and RCC risk. In addition, when the studies were stratified by ethnicity, the significant results were found only in Asian populations in allele model: pooled OR=1.23, 95% CI: 1.08-1.41; homozygote model: pooled OR=1.46, 95% CI: 1.10-1.91; heterozygote model: pooled OR=1.30, 95% CI: 1.06-1.60; dominant model: pooled OR=1.34, 95% CI: 1.11-1.62 (Figure [6](#F6){ref-type="fig"}).

![Forest plot of the association between the +405C/A polymorphism and RCC risk\
**(A)** allele model; **(B)** homozygote model; **(C)** heterozygote model; **(D)** dominant model.](oncotarget-08-50034-g006){#F6}

-1154G/A and RCC risk {#s2_9}
---------------------

In all genetic models, no significant differences was found in VEGF -1154G/A mutation for RCC risk.

VEGF genetic polymorphisms and prognosis of RCC {#s2_10}
-----------------------------------------------

Because of the large number of studies evaluating the relationship of three individual VEGF polymorphisms (VEGF -2578C/A, −1154G/A and -634C/G; individual details in Table [2](#T2){ref-type="table"}) and the prognosis of RCC, meta-analyses were performed separately on these polymorphisms. As a result, VEGF -1154G/A and -634C/G polymorphisms were found significantly associated with poor OS in homozygote model (−1154G/A: HR = 2.30, 95% CI = 1.25-4.24; -634C/G: HR = 1.94, 95% CI = 1.35-2.77). However, no significant differences was detected in VEGF -2578C/A polymorphism (HR = 1.34, 95% CI = 0.96-1.88) (Figure [7](#F7){ref-type="fig"}).

![Forest plot of the association between -2578C/A, −1154G/A and -634C/G polymorphism and the overall survival of RCC](oncotarget-08-50034-g007){#F7}

Sensitivity analysis {#s2_11}
--------------------

Individual studies were consecutively omitted in the sensitivity analysis to detect the influence of each study on the pooled OR. The sensitivity analysis for the results of VEGF genetic polymorphisms and RCC risk demonstrated that the obtained results were statistically robust and no individual study affected the pooled OR significantly.

Publication bias {#s2_12}
----------------

The Begg\'s funnel plot and Egger\'s test were applied to assess the publication bias of the literature in the meta-analysis. As illustrated in Figure [8](#F8){ref-type="fig"}, the shapes of funnel plots showed no evidence of obviously asymmetrical, indicating no evidence of publication bias in dominant model (−2578C/A, *P*=0.573; +936C/T, *P*=0.652; +405 G/C, *P*= 0.602). Moreover, no publication bias was found in test for -2578C/A, −1154G/A, −634C/G on survival. Therefore, our results were reliable according to the overall findings.

![Begg\'s funnel plot of publication bias test in the dominant model\
**(A)** -2578C/A polymorphism; **(B)** +936C/A polymorphism; **(C)** +405C/A polymorphism.](oncotarget-08-50034-g008){#F8}

DISCUSSION {#s3}
==========

As a multifunctional cytokine, VEGF plays a crucial role in the regulation of angiogenesis which has attracted attention because of its involvement in the development of some common cancers \[[@R8], [@R35]\]. VEGF could promote endothelial cell proliferation and the development of new blood vessels \[[@R36]\]. The process of carcinogenesis might be accelerated when the VEGF gene expression was influenced by some functional gene variations. Moreover, the serum VEGF levels from cancer patients were significantly higher than those without signs of cancer \[[@R37]\]. There are several polymorphisms in the VEGF gene and previous studies have indicated many polymorphisms are correlated with various types of cancer including gastric, lung, prostate, breast and renal cancer \[[@R38]--[@R40]\]. VEGF gene polymorphisms could influence the susceptibility, tumor grade and OS of cancer \[[@R22], [@R41]\].

Renal cancer is one of the most common cancers, and it is a major clinical and societal problem in the world \[[@R1]\]. There is growing evidence that aberrations in VEGF contribute to RCC \[[@R42]\]. Moreover, RCC accounts for 2-3% of human cancer and is mainly attributed to the frequent mutations of the von HippelLindau (VHL) tumor suppressor gene \[[@R43]\]. During the past several years, many case-control studies published have assessed the associations of VEGF polymorphisms with the risk of renal cancer, but the findings were inconsistent \[[@R23]--[@R26]\]. A case-control study in a Chinese population indicated that individuals with the AA genotype and A allele of -2578C/A significantly increased the risk of RCC, when compared with the CC genotype \[[@R24]\]. However, another case-control study showed -2578C/A polymorphism did not appear to exert a significant influence on the risk of RCC \[[@R28]\].

A recent meta-analysis suggested that VEGF +936C/T, +1612G/A, −1154G/A, −2549I/D, −460T/C and +405G/C gene polymorphisms were not associated with the risk of RCC, while -2578C/A gene polymorphism might increase the risk under specific genetic models \[[@R44]\]. However, the author only reviewed 5 studies. Another meta-analysis showed that the +936C/T and -2578C/A polymorphisms of VEGF were associated with an increased risk for renal cell carcinoma \[[@R45]\]. However, none of the two meta-analysis found the significant association between VEGF +405G/C gene polymorphisms and RCC risk due to limited published studies, and the latter meta-analysis did not perform the subgroup analysis. Thus, the conclusion in the previous studies was still inaccurate. In addition, those authors failed to assess the predictive value of VEGF polymorphisms in the prognosis of RCC. In recent years, more studies have evaluated the connection between VEGF polymorphisms and the risk and prognosis of RCC \[[@R23]--[@R27]\]. To the best of our knowledge, the sample size in the meta-analysis is larger than any individual study, making more precise and robust results. Thus, the present meta-analysis aimed to provide a more powerful and reliable conclusion about the relationship between VEGF genetic polymorphisms and RCC susceptibility.

This meta-analysis of individual patient data showed that VEGF -2578C/A, +936C/T, +405G/C polymorphisms correlated with an elevated risk of RCC, indicating that these polymorphisms might be risk factors for RCC, especially in Asian populations. However, no statistically significant association was found between -634G/C, −1154G/A, +1612G/A polymorphisms and RCC risk. Interestingly, VEGF +460T/C polymorphism was found significantly associated with susceptibility of RCC, only in Asian populations. Though the exact mechanism of ethnic differences was unknown, a possible reason could be genetic drift and natural selection \[[@R46]\].

To investigate the association between VEGF variants and the prognosis of RCC, 4 independent case-control studies were included with a total of 1,191 RCC cases, the results revealed that significant differences were found in VEGF -1154G/A and -634C/G polymorphisms. Nevertheless, VEGF -2578C/A mutation was not significantly associated with poor OS. The discrepancy is likely that -2578C/A is involved in RCC initiation, and VEGF -1154G/A and -634C/G are involved in progression or treatment response, or tumor heterogeneity \[[@R47]\].

To a certain extent, some limitations should also be emphasized when interpreting the data. (1) Most populations included in this meta-analysis were Asian and Caucasian ethnicity, and more populations from other ethnicities will be required in the future research. (2) The number of included studies in some subgroups was relatively small, with limited statistical power to investigate the real association. More studies by standardized unbiased methods are required, which can offer more detailed individual data of high quality. (3) Adjusted estimates could not be performed in our meta-analysis without enough data for the adjustment by other RCC covariates such as age, life-style and so on. (4) No available data assessing the association between VEGF genetic polymorphisms and the OS of RCC was obtained in some included studies. Therefore, further high-quality researches in RCC prognosis might be performed to draw more accuracy results in subsequent years.

CONCLUSION {#s4}
==========

In summary, the results of the current meta-analysis indicated that VEGF -2578C/A, +936C/T, +405 G/C polymorphisms were associated with an elevated susceptibility to RCC, indicating that these three polymorphisms might be risk factors for RCC, especially in Asian populations. Moreover, VEGF -1154G/A and -634C/G polymorphisms were found significantly associated with poor prognosis of RCC and might become a predicted biomarker in the future. Additional high-quality and multicenter studies with larger sample sizes are needed to confirm our findings in subsequent articles.

MATERIALS AND METHODS {#s5}
=====================

According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), we performed a comprehensive search based on PubMed, EMBASE and Web of Science obtain relevant studies published until August 1st, 2016. The combination of the following search items and MeSH terms were utilized: "vascular endothelial growth factor" or "VEGF", "polymorphism" or "mutation", "variants" and "renal cell carcinoma" or "kidney cancer". Other potentially eligible literature were collected by manually searching from relevant reviews and the references of original studies included for the meta-analysis. Besides, all remaining articles were checked to prevent overlapping datasets. Furthermore, because the data was from previously published studies, ethical approval and informed consent were not required.

Eligible studies were selected according to the following inclusion criteria: (1) Independent case-control or cohort studies; (2) The association between VEGF variants and the risk and the prognosis of RCC; (3) Inclusion of adequate data on frequency of genotypes including ORs and the their 95% CIs. In addition, the study did not meet the inclusion criteria was excluded.

Data extraction {#s5_1}
---------------

According to the above the inclusion criteria, two investigators (Tang JY and Qin ZQ) independently extracted available data from the eligible studies identified, and any disagreements were resolved by discussion with a third reviewer until a consensus was reached. All the extracted information were recorded in a standardized form and the extracted elements included: year of publication, first author\'s last name, ethnicity, source of controls, genotyping assay, the number of cases and controls, the number of VEGF gene polymorphisms carriers and non-carriers respectively, and the results of the Hardy-Weinberg equilibrium (HWE) test.

Quality assessment {#s5_2}
------------------

The quality of the studies was assessed using the validated Newcastle-Ottawa Scale (NOS) for nonrandomized studies. A study can be awarded a maximum of one star for each point within the selection and exposure categories, and a maximum of two stars can be given for comparability. We considered studies with scores of more than 5 as high-quality studies and only high-quality studies were included in our meta-analysis.

Statistical analysis {#s5_3}
--------------------

The strength of association between VEGF mutations and RCC susceptibility was evaluated by the pooled odds ratios (ORs) with 95% confidence intervals (CIs) based on five genetic comparison models: allele model, homozygous model, heterozygous model, dominant model and recessive model. For the primary assessment of the association between VEGF polymorphisms and the overall survival (OS) of RCC, we used the overall hazard ratios (HRs). The goodness-of-fit chi-square test was adopted to assess HWE in controls and P\<0.05 was regarded as significant disequilibrium. The pooled ORs were calculated either with fixed-effects model (a Mantel-Haenszel method) or with the random-effects model (a DerSimonian-Laird method) according to the *P* values of study heterogeneities. If there was no indication of substantial heterogeneity, the fixed-effects model would be conducted. Otherwise, the random effects model was selected to perform this meta-analysis. Then subgroup analysis according to ethnicity was further carried out to explore the potential sources of heterogeneity. To examine the stability and reliability of the overall meta-analysis results, sensitivity analysis was performed by excluding one single study one by one and recalculating their ORs. In addition, Begg\'s funnel plots and Egger\'s linear regression test were employed to search for publication bias between the studies, and *P* values were deemed as a significantly selective bias when less than 0.05. STATA software (version 12.0; StataCorp LP, College Station, TX) was utilized to deal with all above statistical analyses.
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